Abstract
In this issue, Su et al. ([1][1]) present the results of studies of early cellular changes in response to gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in cell lines and a preliminary xenograft model. The EGFR pathway family has been implicated in the pathogenesis
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
